J&J's Darzalex sales disappoint slightly
Johnson & Johnson’s third-quarter sales of the Genmab drug Darzalex, from which the Danish biotech company receives royalties, were slightly lower than expected.
by marketwire
Darzalex sales at Genmab’s partner Johnson & Johnson in the third quarter amounted to USD 2.5bn. This was slightly lower than expected, as analysts’ expectations were USD 2.57bn, according to Bloomberg.
The figures are stated in the financial report from Johnson & Johnson.
In Q3 last year, Darzalex revenue totaled USD 2.052bn.
(Translated using DeepL with additional editing by Kristoffer Grønbæk)
